Adding anti-HER2 therapy after surgery for early-stage gastric cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a targeted therapy (anti-HER2) to standard chemotherapy after surgery can improve outcomes for people with early-stage gastric cancer that has high HER2 levels. It aims to see if the combination is more effective than chemotherapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have stage IB or II gastric cancer that tests positive for HER2
- You have had surgery to remove the tumor and are planning to receive adjuvant treatment afterward
- Your overall health is good enough to tolerate treatment, including normal blood counts, liver, kidney, and heart function
- You have not had other types of cancer in the past 5 years (except for very early skin or cervical cancer)
- You do not have serious heart, lung, or other uncontrolled medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (serplulimab), a targeted HER2 therapy (trastuzumab), and chemotherapy (SOX) after stomach cancer surgery. The goal is to see if this combination reduces the chance of cancer returning in people with HER2-positive stomach cancer.
This Phase 2 trial studies whether adding two medicines (XELOX and tislelizumab) and another chemotherapy drug (PLD) around the time of surgery works better and is safe for people with stage III gastric (stomach) cancer. It is designed for tumors that are HER2-negative and PD-1/L1 positive.
This trial tests adding pembrolizumab to standard trastuzumab and chemotherapy for people with HER2-positive stomach or esophageal cancer that can be fully removed with surgery. The goal is to see if this combination improves outcomes before and after surgery.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This trial tests whether adding the targeted drug pyrotinib to the standard HER2-targeted medicine trastuzumab after surgery can help lower the chance of early-stage HER2-positive breast cancer coming back.
Hear when a new IB-II Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.